Product logins

Find logins to all Clarivate products below.


Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), dominating current treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., J&J Innovative Medicine’s Akeega, Pfizer’s talazoparib) and radioligand therapies (Novartis’s Pluvicto), and anticipated approvals of emerging therapies (e.g., AstraZeneca’s saruparib and Merck’s opevesostat), will drive robust market growth over the 2024-2034 forecast period.

Questions answered

  • What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?
  • How will the prostate cancer market evolve over the 10-year forecast period? What are their drivers and constraints?
  • What are interviewed experts’ insights on the current treatment options for prostate cancer?· How will the adoption and anticipated label expansions of biomarker-driven therapies, such as PARP inhibitors and PSMA-targeted radionuclide therapies, reshape the prostate cancer treatment landscape?
  • What is the clinical and commercial potential of emerging regimens, like opevesostat and saruparib? How are they likely to be positioned in the market?

Geography: United States, EU5, Japan

Primary research: 18 country-specific interviews with thought-leading medical oncologists and urologists; supported by survey data collected for this and other Clarivate research

Epidemiology: Incidence of prostate cancer by country, segmented by risk of biochemical recurrence and TNM staging; market-relevant drug-treatable and drug-treated populations

Forecast: 10-year, annualized, drug-level sales and patient share of key prostate cancer therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents


Related Market Assessment Reports

Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…